Flexibility and Control > Working Together To Halt Diabetes

• Alone — Prandin^® significantly reduces PPG and FPG for lower HbA_1c when used as monotherapy (p<0.05).^1,2
• In combination — Prandin^® used with metformin provides greater glycemic control than either agent alone.³
• "Treat-when-you-eat" dosing — with small, easily-swallowed tablets, Prandin^® is given when patients need it most — before a meal. Patients may be dosed 2,3, or 4 times a day, taken 0 to 30 minutes before meals.

In clinical trials, the most common adverse events leading to discontinuation of PRANDIN^® therapy were hyperglycemia, hypoglycemia, and related symptoms. The most common other side effects reported were cold-and flu-like symptoms, headache, diarrhea, joint ache, and back pain.

Patients who miss a meal or add an extra meal should be instructed to miss (or add) a dose for that meal. The maximum recommended daily dose is 16 mg.

*A 3-month, multicenter, randomized, double-blind, placebo-controlled dose-titration study in patients with type 2 diabetes, with weekly increments of 0.25 mg, 0.5 mg, 1 mg, and 2 mg, up to a maximum dose of 4 mg preprandially or until FPG<160 mg/dL was achieved (Prandin^®, n=66; placebo, n=33).

References

1. Goldberg RB, Einhorn D, Lucas CP, et al. A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes. Diabetes Care. 1998;21:1897-1903.
2. PRANDIN^® Prescribing Information, Novo Nordisk Pharmaceuticals, Inc.
3. Moses R, Slobodniuk R, Boyages S, et al. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 1999; 22:119-124.